Title: 2025-2026 Regular Session HR 220 PN 1564 Bill Text (HTM)
Official Title: 
Number of Sections: 1
Source: versions - Printer's No. PN1564
Media Type: text/html

================================================================================

Section 1:
2025-2026 Regular Session HR 220 PN 1564 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 1564 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.220 Session of 2025 INTRODUCED BY DELLOSO, WAXMAN, SCHLOSSBERG, VENKAT, HILL-EVANS, KAZEEM, PROBST, SANCHEZ AND NEILSON, APRIL 30, 2025 REFERRED TO COMMITTEE ON HUMAN SERVICES, MAY 1, 2025 A RESOLUTIONDesignating the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.WHEREAS, Many people with serious mental health conditions, such as bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder, or with gastrointestinal disorders, including gastroparesis, upset stomach, nausea and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics and antiemetics; andWHEREAS, While ongoing treatment with these medications can be necessary, prolonged use is associated with tardive dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso, limbs, fingers or toes; andWHEREAS, Even mild symptoms of TD can impact people physically, socially and emotionally; andWHEREAS, It is estimated that TD affects approximately 800,000 people in the United States and approximately 60% of 123456789101112131415161718 people with TD have not been diagnosed, making it important to raise awareness about the symptoms; andWHEREAS, It is important that people taking DRBA medication be monitored for TD by a health care provider; andWHEREAS, The American Psychiatric Association recommends regular screenings for TD; andWHEREAS, Clinical research has led to approval of treatments for adults with TD by the United States Food and Drug Administration; andWHEREAS, Recognition and treatment of TD can make a positive impact in the lives of many people experiencing psychotic and mood disorders; andWHEREAS, The House of Representatives wants to raise awareness of TD among the public and medical community; therefore be itRESOLVED, That the House of Representatives designate the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania; and be it furtherRESOLVED, That the House of Representatives encourage people in this Commonwealth and across the United States to become better informed about and aware of tardive dyskinesia.20250HR0220PN1564 - 2 - 123456789101112131415161718192021


================================================================================

Raw Text:
2025-2026 Regular Session HR 220 PN 1564 Bill Text (HTM) See other bills under thesame topic PRINTER'S NO. 1564 THE GENERAL ASSEMBLY OF PENNSYLVANIAHOUSE RESOLUTION No.220 Session of 2025 INTRODUCED BY DELLOSO, WAXMAN, SCHLOSSBERG, VENKAT, HILL-EVANS, KAZEEM, PROBST, SANCHEZ AND NEILSON, APRIL 30, 2025 REFERRED TO COMMITTEE ON HUMAN SERVICES, MAY 1, 2025 A RESOLUTIONDesignating the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania.WHEREAS, Many people with serious mental health conditions, such as bipolar disorder, major depressive disorder, schizophrenia and schizoaffective disorder, or with gastrointestinal disorders, including gastroparesis, upset stomach, nausea and vomiting, may be treated with medications that work as dopamine receptor blocking agents (DRBAs), including antipsychotics and antiemetics; andWHEREAS, While ongoing treatment with these medications can be necessary, prolonged use is associated with tardive dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso, limbs, fingers or toes; andWHEREAS, Even mild symptoms of TD can impact people physically, socially and emotionally; andWHEREAS, It is estimated that TD affects approximately 800,000 people in the United States and approximately 60% of 123456789101112131415161718 people with TD have not been diagnosed, making it important to raise awareness about the symptoms; andWHEREAS, It is important that people taking DRBA medication be monitored for TD by a health care provider; andWHEREAS, The American Psychiatric Association recommends regular screenings for TD; andWHEREAS, Clinical research has led to approval of treatments for adults with TD by the United States Food and Drug Administration; andWHEREAS, Recognition and treatment of TD can make a positive impact in the lives of many people experiencing psychotic and mood disorders; andWHEREAS, The House of Representatives wants to raise awareness of TD among the public and medical community; therefore be itRESOLVED, That the House of Representatives designate the week of May 4 through 10, 2025, as "Tardive Dyskinesia Awareness Week" in Pennsylvania; and be it furtherRESOLVED, That the House of Representatives encourage people in this Commonwealth and across the United States to become better informed about and aware of tardive dyskinesia.20250HR0220PN1564 - 2 - 123456789101112131415161718192021